| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline TJ Smith, J Khatcheressian, GH Lyman, H Ozer, JO Armitage, L Balducci, ... J Clin Oncol 24 (19), 3187-3205, 2006 | 1587 | 2006 |
| Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, ... Journal of Clinical Oncology 26 (21), 3523-3529, 2008 | 966 | 2008 |
| An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative … CH Weaver, B Hazelton, R Birch, P Palmer, C Allen, L Schwartzberg, ... | 790 | 1995 |
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ... Journal of clinical oncology 32 (21), 2240-2247, 2014 | 774 | 2014 |
| First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study CL Vogel, MZ Wojtukiewicz, RR Carroll, SA Tjulandin, ... Journal of Clinical Oncology 23 (6), 1178-1184, 2005 | 627 | 2005 |
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) PH Coluzzi, L Schwartzberg, JD Conroy Jr, S Charapata, M Gay, ... Pain 91 (1), 123-130, 2001 | 499 | 2001 |
| Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ... Journal of clinical oncology 36 (9), 884, 2018 | 479 | 2018 |
| NCCN guidelines insights: breast cancer, version 1.2017 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the national comprehensive cancer network 15 (4), 433-451, 2017 | 473 | 2017 |
| Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma KS Robinson, ME Williams, RH van der Jagt, P Cohen, JA Herst, ... Journal of Clinical Oncology 26 (27), 4473-4479, 2008 | 432 | 2008 |
| Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018 | 430 | 2018 |
| Defining a therapeutic dose of peripheral blood stem cells JG Bender, LB To, S Williams, LS Schwartzberg Journal of hematotherapy 1 (4), 329-341, 1992 | 413 | 1992 |
| Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016 | 373 | 2016 |
| Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer J O'Shaughnessy, L Schwartzberg, MA Danso, KD Miller, HS Rugo, ... Journal of clinical oncology 32 (34), 3840-3847, 2014 | 360 | 2014 |
| A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J O'shaughnessy, LS Schwartzberg, MA Danso, HS Rugo, K Miller, ... Journal of Clinical Oncology 29 (15_suppl), 1007-1007, 2011 | 343 | 2011 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 338 | 2019 |
| Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions SB Streeter, L Schwartzberg, N Husain, M Johnsrud Journal of oncology practice 7 (3S), 46s-51s, 2011 | 286 | 2011 |
| A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea … M Aapro, H Rugo, G Rossi, G Rizzi, ME Borroni, I Bondarenko, T Sarosiek, ... Annals of oncology 25 (7), 1328-1333, 2014 | 279 | 2014 |
| Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer LS Schwartzberg, SX Franco, A Florance, L O'Rourke, J Maltzman, ... The oncologist 15 (2), 122-129, 2010 | 267 | 2010 |
| Breast cancer version 2.2015 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 13 (4), 448-475, 2015 | 248 | 2015 |
| Precision oncology: who, how, what, when, and when not? L Schwartzberg, ES Kim, D Liu, D Schrag American Society of Clinical Oncology Educational Book 37, 160-169, 2017 | 247 | 2017 |
